Get the Stockscreener App
296.88
0.60%
1.78
After Hours:
297.30
0.42
+0.14%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $296.88, with a volume of 2.41M.
It is up +0.60% in the last 24 hours and up +2.19% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$295.10
Open:
$297.06
24h Volume:
2.41M
Relative Volume:
0.93
Market Cap:
$159.63B
Revenue:
$34.13B
Net Income/Loss:
$5.93B
P/E Ratio:
27.09
EPS:
10.96
Net Cash Flow:
$10.92B
1W Performance:
-3.16%
1M Performance:
+2.19%
6M Performance:
+4.02%
1Y Performance:
-11.52%
1-Day Range:
$292.59
$298.52
1-Week Range:
$292.59
$306.00
52-Week Range:
$253.30
$339.17
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
296.88 | 158.68B | 34.13B | 5.93B | 10.92B | 10.96 |
|
LLY
Lilly Eli Co
|
762.33 | 664.39B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
167.33 | 396.75B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
195.22 | 333.89B | 58.33B | 3.76B | 15.39B | 2.10 |
|
NVS
Novartis Ag Adr
|
115.30 | 220.18B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
79.29 | 196.16B | 63.62B | 16.41B | 17.04B | 6.49 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen (AMGN) Board Declares US$2.38 Dividend for Q3 2025 - simplywall.st
Moors & Cabot Inc. Decreases Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Heritage Wealth Advisors Cuts Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Commerce Bank - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Empirical Financial Services LLC d.b.a. Empirical Wealth Management - MarketBeat
Hoxton Planning & Management LLC Purchases Shares of 968 Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Baader Bank Aktiengesellschaft Has $279,000 Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Bought by XTX Topco Ltd - MarketBeat
Federated Hermes Inc. Has $634.68 Million Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
UBS Raises PT on Amgen Inc. (AMGN) to $326 From $315, Keeps a Neutral Rating - MSN
Amgen Announces $2.38 Per Share Dividend Payout: Key Dates and Details Revealed - Stock Titan
Amgen’s Promising Phase 3 Study on Dazodalibep for Sjögren’s Syndrome: A Potential Game-Changer - TipRanks
Amgen’s Latest Clinical Study: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks
Amgen’s Tarlatamab Study: A Potential Breakthrough in SCLC Treatment - TipRanks
Amgen’s Promising Heart Failure Study: A Potential Game-Changer? - TipRanks
Amgen’s Promising Phase 3 Study for Metastatic Colorectal Cancer - TipRanks
Amgen’s New Study on AMG 410: A Potential Game-Changer in Cancer Treatment - TipRanks
Amgen’s New Melanoma Study: A Potential Game Changer? - TipRanks
Amgen’s Tarlatamab Study: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
Amgen’s Promising Phase 3 Study on Weight Loss Drug Maridebart Cafraglutide - TipRanks
Amgen’s Promising Study on Rocatinlimab for Atopic Dermatitis: A Potential Game-Changer - TipRanks
Amgen’s CodeBreaK 202: A New Front-Line Therapy Study for Advanced Lung Cancer - TipRanks
Amgen’s Phase 2 Study on HZN-1116: A Potential Breakthrough for Sjögren’s Syndrome - TipRanks
Amgen’s Golden Gate Study: A Promising Leap in Leukemia Treatment - TipRanks
Amgen’s Phase 3 Obesity Drug Trial: A Potential Game Changer? - TipRanks
Amgen’s New Study on ABP 234: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
Is Amgen (NASDAQ:AMGN) A Risky Investment? - simplywall.st
Torray Investment Partners LLC Trims Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Natixis Advisors LLC Has $101.15 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Arkadios Wealth Advisors Boosts Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Dearborn Partners LLC Has $654,000 Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Why Amgen Inc. stock attracts strong analyst attentionReliable Breakout Signal Guide Signal - beatles.ru
Geneos Wealth Management Inc. Purchases 5,500 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Mitchell Sinkler & Starr PA Reduces Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Foundations Investment Advisors LLC Increases Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Mackenzie Financial Corp Has $55.12 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
What markets is CRUS expanding into Is Amgen Inc. stock a good long term investment optionBeginner Investor Report With Low Risk - jammulinksnews.com
Amgen Sets Q2 2025 Earnings Call: CEO Bradway to Present Financial Results August 5 - Stock Titan
Amgen’s Promising Oncology Study: A Closer Look at AMG 193 and IDE397 - TipRanks
Why is Amgen Inc. stock attracting strong analyst attentionRetirement Planning Review With Proven Results - jammulinksnews.com
Gear Up for Amgen (AMGN) Q2 Earnings: Wall Street Estimates for Key Metrics - Yahoo.co
Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial - Yahoo Finance
Howard Capital Management Inc. Has $5.58 Million Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Tredje AP fonden Increases Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Vestcor Inc Sells 6,075 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
TD Asset Management Inc Sells 27,366 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Purkiss Capital Advisors LLC Buys Shares of 863 Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Mediolanum International Funds Ltd Sells 3,230 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by TCW Group Inc. - MarketBeat
ARK Investment Management LLC Trims Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Assetmark Inc. Sells 118,002 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):